Rockefeller Capital Management’s Galectin Therapeutics GALT Stock Holding History

Rockefeller Capital Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.2K	Hold	4,386	–	–	﹤0.01%	3908
2025 Q4	$18.2K	Hold	4,386	–	–	﹤0.01%	3552
2025 Q3	$18.6K	Buy	+4,386	New	+$16.5K	﹤0.01%	3381
2023 Q1	–	Sell	-8,886	Closed	-$10K	–	2710
2022 Q4	$10K	Hold	8,886	–	–	﹤0.01%	3073
2022 Q3	$14K	Hold	8,886	–	–	﹤0.01%	2929
2022 Q2	$11K	Hold	8,886	–	–	﹤0.01%	3063
2022 Q1	$14K	Sell	8,886 -4,000	-31%	-$7.74K	﹤0.01%	2885
2021 Q4	$26K	Hold	12,886	–	–	﹤0.01%	2513
2021 Q3	$49K	Buy	12,886 +2,500	+24%	+$8.47K	﹤0.01%	2148
2021 Q2	$33K	Buy	10,386 +8,386	+419%	+$29.8K	﹤0.01%	2257
2021 Q1	$4K	Hold	2,000	–	–	﹤0.01%	2962
2020 Q4	$4K	Hold	2,000	–	–	﹤0.01%	2488
2020 Q3	$5K	Hold	2,000	–	–	﹤0.01%	2218
2020 Q2	$6K	Hold	2,000	–	–	﹤0.01%	2030
2020 Q1	$4K	Hold	2,000	–	–	﹤0.01%	2012
2019 Q4	$6K	Buy	+2,000	New	+$6.95K	﹤0.01%	1740

Other funds holding GALT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Rockefeller Capital Management's GALT Position: Q1 2026 in Review

Rockefeller Capital Management held its Galectin Therapeutics (GALT) position steady in Q1 2026 at 4,386 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3908.

Rockefeller Capital Management first reported a position in GALT in Q4 2019 and has held it in 16 quarters since. The position peaked at $49K in Q3 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

Rockefeller Capital Management held 4,386 shares of Galectin Therapeutics worth $12.2K as of Q1 2026.
Rockefeller Capital Management left its Galectin Therapeutics share count unchanged in Q1 2026.
Galectin Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3908 holding.
Rockefeller Capital Management first reported a position in Galectin Therapeutics in Q4 2019 and has held it in 16 quarters since.
Rockefeller Capital Management's Galectin Therapeutics position peaked at $49K in Q3 2021.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.